| Symbol | TPST |
|---|---|
| Name | TEMPEST THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 7000 SHORELINE COURT,SUITE 275, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 415 798-8589 |
| Fax | — |
| — | |
| Website | https://www.tempesttx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001544227 |
| Description | Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Additional info from NASDAQ: |
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Read moreNew Form DEF 14A - Tempest Therapeutics, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001140361-26-028823 <b>Size:</b> 1 MB
Read moreNew Form 424B3 - Tempest Therapeutics, Inc. <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001193125-26-298528 <b>Size:</b> 152 KB
Read moreNew Form EFFECT - Tempest Therapeutics, Inc. <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 9999999995-26-002212 <b>Size:</b> 1 KB
Read moreNew Form PRE 14A - Tempest Therapeutics, Inc. <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001140361-26-027791 <b>Size:</b> 1 MB
Read moreAngel Matthew 🟢 acquired 694.4K shares (2 derivative) of Tempest Therapeutics, Inc. (TPST) at $2.16 ($1.5M) Transaction Date: Mar 24, 2026 | Filing ID: 279703
Read moreYee John D. 🟢 acquired 25.0K shares (1 derivative) of Tempest Therapeutics, Inc. (TPST) at $1.27 Transaction Date: Jun 04, 2026 | Filing ID: 274545
Read moreNew Form 3 - Tempest Therapeutics, Inc. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001193125-26-274538 <b>Size:</b> 3 KB
Read moreRichey William Drake 🟢 acquired 25.0K shares (1 derivative) of Tempest Therapeutics, Inc. (TPST) at $1.27 Transaction Date: Jun 04, 2026 | Filing ID: 262257
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unrese… | Phase3 | Hepatocellular Carcinoma (HCC) | Not_Yet_Recruiting | 2025-12-01 | 2030-07-01 | ClinicalTrials.gov |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembro… | Phase1 | Solid Tumor | Completed | 2020-05-06 | 2024-09-25 | ClinicalTrials.gov |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Adv… | Phase1 | Hepatocellular Carcinoma | Completed | 2019-03-20 | 2022-09-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Part 4 TPST-1120 + nivolumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT03829436 |
| Part 3 TPST-1120 | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT03829436 |
| Part 2 TPST-1120 + nivolumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT03829436 |
| Part 1 TPST-1120 | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT03829436 |
| Bevacizumab | Other | Phase PHASE3 | Hepatocellular Carcinoma (HCC) | NOT_YET_RECRUITING | NCT06680258 |
| Atezolizumab | Other | Phase PHASE3 | Hepatocellular Carcinoma (HCC) | NOT_YET_RECRUITING | NCT06680258 |
| TPST-1120 | Other | Phase PHASE3 | Hepatocellular Carcinoma (HCC) | NOT_YET_RECRUITING | NCT06680258 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04344795 |
| TPST-1495 once daily or on intermittent schedule | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04344795 |
| TPST-1495 twice daily | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04344795 |